Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

Alberto Lleo*, Daniel Alcolea, Pablo Martinez-Lage, Philip Scheltens, Lucilla Parnetti, Judes Poirier, Anja H. Simonsen, Marcel M. Verbeek, Pedro Rosa-Neto, Rosalinde E. R. Slot, Mikel Tainta, Andrea Izaguirre, Babette L. R. Reijs, Lucia Farotti, Magda Tsolaki, Rik Vandenbergue, Yvonne Freund-Levi, Frans R. J. Verhey, Jordi Clarimon, Juan ForteaLutz Frolich, Isabel Santana, Jose Luis Molinuevo, Sylvain Lehmann, Pieter J. Visser, Charlotte E. Teunissen, Henrik Zetterberg, Kaj Blennow

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

56 Citations (Web of Science)
21 Downloads (Pure)

Abstract

Introduction: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined.

Methods: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL). Median CSF sampling interval was 2.1 years.

Results: CSF levels of t-tau, p-tau, NfL, and YKL-40 were 2% higher per each year of baseline age in controls (P

Discussion: All four CSF biomarkers increase with age, but this effect deviates in AD for t-tau and ptau. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)742-753
Number of pages12
JournalAlzheimer's & Dementia
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 2019

Keywords

  • Alzheimer
  • CSF
  • Tau
  • Amyloid
  • Neurofilaments
  • Inflammation
  • YKL-40
  • NEUROFILAMENT LIGHT
  • ASSOCIATION WORKGROUPS
  • DIAGNOSTIC GUIDELINES
  • NATIONAL INSTITUTE
  • CSF BIOMARKERS
  • TAU LEVELS
  • RECOMMENDATIONS
  • PROTEIN
  • BETA
  • DEMENTIA

Cite this